Immungenetics AG is a clinical-stage biopharmaceutical company founded in 2009. Specializing in the Biotechnology industry, the company is dedicated to developing effective treatments for neurodegenerative diseases. As a venture capital firm, it is crucial to keep an eye on Immungenetics AG's progress, especially in the field of neurodegenerative disease treatments, as it signifies potential breakthroughs in the healthcare sector. With a focus on cutting-edge research and development, Immungenetics AG holds promise for significant advancements in the treatment of neurodegenerative conditions. Although details about their headquarters and last investment are currently undisclosed, their innovative approach to combating neurodegenerative diseases makes them a compelling prospect for potential investment opportunities in the biopharmaceutical sector.
There is no investment information
No recent news or press coverage available for Immungenetics AG.
We care about your data, and we'd love to use cookies make your experience better.
